Global Rank
#19184
Country Rank
#247
Market Cap
226.35 M
Price
0.96
Change (%)
1.48%
Volume
269,529
Vicore Pharma Holding AB (publ)'s latest marketcap:
226.35 M
As of 06/07/2025, Vicore Pharma Holding AB (publ)'s market capitalization has reached $226.35 M. According to our data, Vicore Pharma Holding AB (publ) is the 19184th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 226.35 M |
| Revenue (ttm) | 618,684 |
| Net Income (ttm) | -32,186,428.8 |
| Shares Out | 234.58 M |
| EPS (ttm) | -0.19 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/22/2025 |
Market Cap Chart
Data Updated: 06/07/2025
Vicore Pharma Holding AB (publ)'s yearly market capitalization.
Vicore Pharma Holding AB (publ) has seen its market value grow from kr1.9 B to kr2.19 B since 2020, representing a total increase of 15.25% and an annual compound growth rate (CAGR) of 3.25%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/07/2025 | kr2.19 B | 10.65% |
| 12/30/2024 | kr1.98 B | 25.12% |
| 12/29/2023 | kr1.58 B | 8.13% |
| 12/30/2022 | kr1.47 B | 46.67% |
| 12/30/2021 | kr998.9 M | -47.51% |
| 12/30/2020 | kr1.9 B |
Company Profile
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company focused on developing innovative therapies for respiratory diseases.
Key Developments
- C21: An orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in Phase II clinical trials for idiopathic pulmonary fibrosis (IPF) and Phase I trials for pulmonary arterial hypertension.
- Almee: An investigational medical device that has completed Phase III clinical trials, targeting the psychological impact of living with pulmonary fibrosis.
Strategic Collaborations
- Partnership with Emeriti Bio AB and HaLaCore Pharma AB to develop follow-on molecules based on C21 and other AT2 receptor-targeting drug substances.
- Collaboration with Alex Therapeutics AB to create a digital app for interstitial lung diseases, including IPF.
Company Background
Formerly known as Mintage Scientific AB, Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Frequently Asked Questions
-
What is Vicore Pharma Holding AB (publ)'s (STO-VICO) current market cap?As of 06/07/2025, Vicore Pharma Holding AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $226.35 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Vicore Pharma Holding AB (publ) (STO-VICO) rank globally by market cap?Vicore Pharma Holding AB (publ) global market capitalization ranking is approximately 19184 as of 06/07/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.